EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

Maria-Cynthia Fuentes-Lacouture iD, Devi Nandana iD, Karthik Ramasamy iD, Anjan Thakurta iD

The FEBS Journal · 2026

DOI: 10.1111/febs.70599 ↗

At a glance

Übersichtsarbeit in The FEBS Journal, 2026. Written by Maria-Cynthia Fuentes-Lacouture and 3 co-authors. Institution: Hospital Militar Central De Bogotá, Bogotá, Colombia. Major MEDLINE topics: Multiple Myeloma, Drug Resistance, Neoplasm, Immunomodulating Agents, Immunologic Factors. 90 references. The full text is freely available (open access, CC BY 4.0). Funded by: Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide in combination with proteasome inhibitors, dexamethasone and anti‐CD38 monoclonal antibodies, play a central role in the treatment of multiple myeloma (MM) across newly diagnosed and relapsed stages. These treatment regimens have significantly improved patient outcomes worldwide, establishing IMiDs as one of the backbones of MM therapy. A new generation of more potent compounds called cereblon E3 ligase modulators (CELMoDs) is now being developed to potentially replace the older IMiDs. In addition, novel immunotherapeutic approaches led by chimeric antigen receptor (CAR T), T‐cell engagers and antibody–drug conjugates are also increasingly used in relapsed and refractory myeloma patient care. However, despite these advances, resistance to IMiD‐based therapies inevitably develops and represents a major clinical challenge. Understanding the biological basis of resistance to IMiD‐based therapy is crucial to plan and maximise treatment options for patients when they relapse on IMiD containing regimens. Emerging evidence underscores the role of genetic and epigenetic alterations, changes in downstream signalling, and dysregulation of the bone marrow immune microenvironment in driving therapeutic resistance. In this review, we explore current literature on the molecular and immune mechanisms related to the onset of therapeutic resistance. We then suggest ways to overcome resistance and exemplify options for the future, focusing on immunotherapy combinations with IMiDs or CELMoDs and novel agents.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaDrug Resistance, NeoplasmImmunomodulating AgentsImmunologic FactorsHumansThalidomideImmunotherapyLenalidomide

Author keywords

CELMoDscombination therapiesepigenetic agentsimmunomodulatory drugs (IMiDs)multiple myelomatherapy resistance

Substances

Immunomodulating AgentsThalidomidepomalidomideImmunologic FactorsLenalidomide

Authors and institutions

  • Hospital Militar Central De Bogotá, Bogotá, Colombia.
  • Oxford Translational Myeloma Centre, Botnar Research Centre, University of Oxford, Oxford, UK.

ORCID profiles: Maria-Cynthia Fuentes-Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta

Funding

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

Cite

APA

Fuentes-Lacouture, M. C., Nandana, D., Ramasamy, K., & Thakurta, A. (2026). Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma. The FEBS Journal. https://doi.org/10.1111/febs.70599

Vancouver

Fuentes-Lacouture MC, Nandana D, Ramasamy K, Thakurta A. Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma. The FEBS Journal. 2026. doi:10.1111/febs.70599

BibTeX
@article{FuentesLacouture2026,
  author = {Fuentes-Lacouture, Maria-Cynthia and Nandana, Devi and Ramasamy, Karthik and Thakurta, Anjan},
  title = {Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma},
  journal = {The FEBS Journal},
  year = {2026},
  doi = {10.1111/febs.70599}
}
Start for free →